tert-butyl N-[N'-[2-(2-tert-butylphenoxy)pyridin-3-yl]-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]carbamate | 901309-28-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl N-[N'-[2-(2-tert-butylphenoxy)pyridin-3-yl]-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]carbamate
• CAS: 901309-28-2
• 化学式: C₂₆H₃₆N₄O₅
• 分子量: 484.596
• InChiKey: VXLKLGTZPYXTBQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  111
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[N'-[2-(2-tert-butylphenoxy)pyridin-3-yl]-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]carbamate 在 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 2-(2-(Tert-butyl)phenoxy)-N-(5-phenyl-1H-imidazol-2-yl)pyridin-3-amine
  参考文献：
  名称：

  2-Aminothiazole based P2Y1 antagonists as novel antiplatelet agents

  摘要：

  ADP receptors, P2Y(1) and P2Y(12) have been recognized as potential targets for antithrombotic drugs. A series of P2Y(1) antagonists that contain 2-aminothiazoles as urea surrogates were discovered. Extensive SAR of the thiazole ring is described. The most potent compound 7j showed good P2Y(1) binding (K-i = 12 nM), moderate antagonism of platelet aggregation (PA IC50 = 5.2 mu M) and acceptable PK in rats. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.025
• 作为产物：
  描述：

  2-氟-3-硝基吡啶 在 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 、 三乙胺 、 mercury dichloride 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 148.0h， 生成 tert-butyl N-[N'-[2-(2-tert-butylphenoxy)pyridin-3-yl]-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]carbamate
  参考文献：
  名称：

  2-Aminothiazole based P2Y1 antagonists as novel antiplatelet agents

  摘要：

  ADP receptors, P2Y(1) and P2Y(12) have been recognized as potential targets for antithrombotic drugs. A series of P2Y(1) antagonists that contain 2-aminothiazoles as urea surrogates were discovered. Extensive SAR of the thiazole ring is described. The most potent compound 7j showed good P2Y(1) binding (K-i = 12 nM), moderate antagonism of platelet aggregation (PA IC50 = 5.2 mu M) and acceptable PK in rats. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.025

文献信息

• Heteroaryl compounds as P2Y1 receptor inhibitors
  申请人：Sutton C. James

  公开号：US20060173002A1

  公开（公告）日：2006-08-03

  The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y 1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y 1 receptor activity.

  本发明提供了新颖的杂环芳基化合物及其类似物，这些化合物是人类P2Y1受体的选择性抑制剂。该发明还提供了相应的各种药物组合物以及调节P2Y1受体活性治疗对其敏感的疾病的方法。
• HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS
  申请人：Sutton James C.

  公开号：US20100093689A1

  公开（公告）日：2010-04-15

  The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y 1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y 1 receptor activity.

  本发明提供了新型杂环芳基化合物及其类似物，它们是选择性抑制人类P2Y1受体的药物。本发明还提供了各种该药物的制剂和调节P2Y1受体活性治疗疾病的方法。
• 2-PHENOXY-N-(1,3,4-THIADIZOL-2-YL)PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1954696A2

  公开（公告）日：2008-08-13
• US7645778B2
  申请人：——

  公开号：US7645778B2

  公开（公告）日：2010-01-12
• US8273772B2
  申请人：——

  公开号：US8273772B2

  公开（公告）日：2012-09-25